Table 3 Relationship between CERS4 status and clinicopathological factors in colorectal cancer patients.
From: Ceramide synthase CERS4 gene downregulation is associated with KRAS mutation in colorectal cancer
Variables | CerS4 high N = 50 | CerS4 low N = 32 | p-value |
|---|---|---|---|
Age (years), median | 67.6 | 68.5 | 0.722 |
Gender (male/female) | 31 (62%)/19 (38%) | 22 (68.8%)/10 (31.3%) | 0.533 |
Tumor location (right side/left side) | 10 (20%)/40 (80%) | 10 (31.3%)/22 (68.8%) | 0.247 |
Histology (well or mod. defined/others) | 48 (96%)/2 (4%) | 31 (96.9%)/1 (3.1%) | 0.837 |
Depth of tumor invasion (T1 or T2/T3 or T4) | 5 (10%)/45 (90%) | 6 (18.8%)/26 (81.3%) | 0.257 |
Lymph node metastasis (+/−) | 23 (46%)/27 (54%) | 12 (37.5%)/20 (62.5%) | 0.448 |
Lymph[atic] invasion (+/−) | 19 (59.4%)/13 (40.6%) | 22 (44%)/28 (56%) | 0.1744 |
Venous invasion (+/−) | 42 (84.0%)/8 (16%) | 18 (56.3%)/14 (43.8%) | 0.0057 |
Distant metastasis (+/−) | 10 (20%)/40 (80%) | 3 (9.4%)/29 (90.6%) | 0.1998 |
CEA [level] (high/normal) | 20 (40%)/30 (60%) | 16 (50%)/16 (50%) | 0.373 |
CA19-9 [level] (high/normal) | 8 (16%)/42 (84%) | 9 (28.1)/23 (71.9%) | 0.1864 |
KRAS (wild-type/mutant) | 35 (70%)/15 (30%) | 11 (34.4%)/21 (65.6%) | 0.0015 |
NRAS (wild-type/mutant) | 32 (100%)/0 (0%) | 48 (96.0%)/2 (4%) | 0.2520 |
BRAF (wild-type/mutant) | 29 (90.6%)/3 (9.4%) | 48 (96%)/2 (4%) | 0.3211 |
